July 10, 2023Open Access

Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3 −/− Mice

Key Points

Key points are not available for this paper at this time.

Abstract

Experiments in mice suggest that triple RAS/SGLT2/MR blockade may substantially improve renal outcomes in Alport syndrome and possibly other progressive CKDs because of synergistic effects on the glomerular and tubulointerstitial compartments.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Zhihui Zhu

Karoline Rosenkranz

Yoshihiro Kusunoki

Journals

Journal of the American Society of Nephrology

Actions

Institutions

Ludwig-Maximilians-Universität München

RWTH Aachen University

University of Florence

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3 −/− Mice

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study